Unlike antibodies against amyloid-β, little is known about serum antibodies to neuron-specific cytoskeletal proteins in patients with Alzheimer's disease (AD).
Objective:
We aimed to study IgG autoantibodies against tau protein, light (NFL) and heavy subunits (NFH) of neurofilaments in serum of AD patients and elderly controls and to explore the evolution of antineurocytoskeletal antibody levels over time.
Methods:
Antibodies against three targets (tau, NFL, and NFH) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls and 49 patients with AD. Our primary cross-sectional design was further extended to monitor fluctuations over 1-2 years in a subset of individuals.
Results:
The AD patients had lower levels of anti-tau antibodies (p = 0.03) and even lower anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03).
Conclusions:
The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower anti-tau levels in these patients. Our findings indicate a special feature of disease-relevant antigens and humoral autoimmunity in AD.
SoussanL, TchernakovK, Bachar-LaviO, YuvanT, WertmanE, MichaelsonDM (1994) Antibodies to different isoforms of the heavyneurofilament protein (NF-H) in normal aging and Alzheimer’sdisease.Mol Neurobiol9, 83-91.
2.
RosenmannH (2012) CSF biomarkers for amyloid and tau pathology inAlzheimer’s disease.J Mol Neurosci47, 1-14.
3.
PetzoldA, KeirG, WarrenJ, FoxN, RossorMN (2007) A systematicreview and meta-analysis of CSF neurofilament protein levels asbiomarkers in dementia.Neurodegener Dis4, 185-194.
4.
PerryG, RizzutoN, Autilio-GambettiL, GambettiP (1985) Pairedhelical filaments from Alzheimer disease patients containcytoskeletal components.Proc Natl Acad Sci U S A82, 3916-3920.
5.
VickersJC, KirkcaldieMT, PhippsA, KingAE (2016) Alterations inneurofilaments and the transformation of the cytoskeleton in smay provide insight into the aberrant neuronal changes of Alzheimer’s disease.Brain Res Bull126, 324-333axon.
6.
HortJ, BartosA, PirttilaT, ScheltensP (2010) Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.Eur J Neurol17, 90-96.
7.
BartosA, CechováL, SvarcováJ, RicnýD (2012) Cerebrospinal fluid triplet in the diagnosis of Alzheimer-Fischer disease.Cesk Slov Neurol N 75/108, 587-594.
8.
D’AndreaMR (2005) Add Alzheimer’s disease to the list of auto immune diseases.Med Hypotheses64, 458-463.
9.
GoniF, SigurdssonEM (2005) New directions towards safer and effective vaccines for Alzheimer’s disease.Curr Opin Mol Ther7, 17-23.
10.
LevinEC, AcharyaNK, HanM, ZavarehSB, SedeynJC, VenkataramanV, NageleRG (2010) Brain-reactive auto antibodies are nearly ubiquitousin human sera and may be linked to pathology in the context of blood-brain barrier break down.Brain Res1345, 221-232.
11.
NageleRG, CliffordPM, SiuG, LevinEC, AcharyaNK, HanM, KosciukMC, VenkataramanV, ZavarehS, ZarrabiS, KinslerK, ThakerNG, NageleEP, DashJ, WangHY, LevitasA (2011) Brain-reactiveautoantibodies prevalent in human sera increase intraneuronal xamyloid-beta(1-42) deposition.J Alzheimers Dis25, 605-622.
ColasantiT, BarbatiC, RosanoG, MalorniW, OrtonaE (2010) Autoantibodies in patients with Alzheimer’s disease: Pathogeneticrole and potential use as biomarkers of disease progression.Autoimmun Rev9, 807-811.
14.
RodriguesMC, SanbergPR, CruzLE, Garbuzova-DavisS (2014) Theinnate and adaptive immunological aspects in neuro degenerative diseases.J Neuroimmunol269, 1-8.
15.
PapucE, Kurys-DenisE, KrupskiW, TataraM, RejdakK (2015) Canantibodies against glial derived antigens be early biomarkers ofhippocampal demyelination and memory loss in Alzheimer’s disease?. J Alzheimers Dis48, 115-121.
16.
GrudenMA, DavidovaTB, MalisauskasM, SewellRD, VoskresenskayaNI, WilhelmK, ElistratovaEI, SherstnevVV, Morozova-RocheLA (2007) Differential neuroimmune markers to the onset of Alzheimer’s disease neuro degeneration and dementia: Autoantibodies to Abeta((25-35))oligomers, S100b and neurotransmitters.J Neuroimmunol186, 181-192.
17.
NoskovaL, FialovaL, BartosA, ZimaT (2017) Avidity of anti neuro cytoskeletal antibodies in Alzheimer’s disease patients.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub161, 179-186.
18.
WuJ, LiL (2016) Autoantibodies in Alzheimer’s disease: Potential biomarkers, pathogenic roles, and therapeutic implications.J Biomed Res30, 361-372.
19.
KumarM, CohenD, EisdorferC (1988) Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome.Alzheimer Dis Assoc Disord2, 50-55.
20.
StefanssonK, MartonLS, DieperinkME, MolnarGK, SchlaepferWW, HelgasonCM (1985) Circulating autoantibodies to the 200,000-daltonprotein of neurofilaments in the serum of healthy individuals.Science228, 1117-1119.
21.
PapucE, KrupskiW, Kurys-DenisE, RejdakK (2016) Antibodies against small heat-shock proteins in Alzheimer’s disease as a partof natural human immune repertoire or activation of humoralresponse?. J Neural Transm (Vienna)123, 455-461.
22.
MichaelsonDM, ChapmanJ, BacharO, KorczynAD, WertmanE (1989) Serum antibodies to cholinergic neurons in Alzheimer’s disease.Prog Clin Biol Res317, 689-694.
RosenmannH, MeinerZ, GeylisV, AbramskyO, SteinitzM (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects.Neurosci Lett410, 90-93.
25.
CongdonEE, KrishnaswamyS, SigurdssonEM (2014) Harnessing theimmune system for treatment and detection of tau pathology.J Alzheimers Dis40 (Suppl 1), S113-S121.
26.
AsuniAA, BoutajangoutA, QuartermainD, SigurdssonEM (2007) Immunotherapy targeting pathological tau conformers in a tanglemouse model reduces brain pathology with associated functional improvements.J Neurosci27, 9115-9129.
27.
BoimelM, GrigoriadisN, LourbopoulosA, HaberE, AbramskyO, RosenmannH (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.ExpNeurol224, 472-485.
28.
BoutajangoutA, SigurdssonEM, KrishnamurthyPK (2011) Tau as atherapeutic target for Alzheimer’s disease.Curr Alzheimer Res8, 666-677.
29.
BoutajangoutA, QuartermainD, SigurdssonEM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a newtangle mouse model.J Neurosci30, 16559-16566.
30.
RosenmannH, GrigoriadisN, KarussisD, BoimelM, TouloumiO, OvadiaH, AbramskyO (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.Arch Neurol63, 1459-1467.
31.
SigurdssonEM (2006) Immunotherapy for conformational diseases.Curr Pharm Des12, 2569-2585.
32.
NovakP, SchmidtR, KontsekovaE, ZilkaN, KovacechB, SkrabanaR, Vince-KazmerovaZ, KatinaS, FialovaL, PrcinaM, ParrakV, Dal-BiancoP, BrunnerM, StaffenW, RainerM, OndrusM, RopeleS, SmisekM, SivakR, WinbladB, NovakM (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase 1 trial.Lancet Neurol16, 123-134.
33.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, Jr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease:Recommendations from the National Institute on Aging-Alzheimer’sAssociation work groups on diagnostic guidelines for Alzheimer’sdisease.Alzheimers Dement7, 263-269.
34.
ScheltensP, LeysD, BarkhofF, HugloD, WeinsteinHC, VermerschP, KuiperM, SteinlingM, WoltersEC, ValkJ (1992) Atrophy of medialtemporal lobes on MRI in “probable” Alzheimer’s disease and normalageing: Diagnostic value and neuropsychological correlates.J Neurol Neurosurg Psychiatry55, 967-972.
35.
BartošsA, ZachP, DiblíkováF, Tintšera J, šRípováD, BrunovskýM (2007) Visual rating of medial temporal lobe atrophy on magnetic resonance imaging in Alzheimer’s disease.Psychiatrie11, 49-52.
36.
SpreenO, StraussE, ShermanEMS (1998), A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, Oxford University Press, New York.
37.
BartosA, RaisovaM (2015) Testy a dot caníky pro vyšetřování kognitivních funkcí, nálady a sobĕBstačnosti.(Tests and questionnaires for assessment of cognitive func-tions, mood and activities of daily living).Mladá Fronta, Prague.
38.
BartosA, RaisovaM (2016) The Mini-Mental State Examination: Czechnorms and cutoffs for mild dementia and mild cognitive impairmentdue to Alzheimer’s disease.Dement Geriatr Cogn Disord42, 50-57.
39.
MioshiE, DawsonK, MitchellJ, ArnoldR, HodgesJR (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): A briefcognitive test battery for dementia screening.Int J Geriatr Psychiatry21, 1078-1085.
40.
Bartošs A, RaisováM, KopešcekM (2011) Novelizacečeské verze Addenbrookského kognitivního testu(ACE-CZ) (Amendment of the Czech Addenbrooke’s cognitive examination(ACE-CZ).Cesk Slov Neurol N74/107, 681-684.
41.
BartošsA, RaisováM, KopešcekM (2011) Důvody aprůběh novelizace české verze Addenbrookskéhokognitivního testu (ACE-CZ). (The Reasons and the Process of Amendment of the Czech Addenbrooke’s Cognitive Examination (ACE-CZ))Cesk Slov Neurol N74/107, e1-e6.
BeránkováD, KrulováP, MrašckováM, EliášsováI, KošstálováM, JanoušsováE, StehnováI, BarM, RessnerP, NiliusP, TomagováM, RektorováI (2015) Addenbrooke’s Cognitive Examination – approximate normal values for the Czechpopulation (in Czech).Cesk Slov Neurol N78/111, 300-305.
44.
SilberE, SemraYK, GregsonNA, ShariefMK (2002) Patients withprogressive multiple sclerosis have elevated antibodies to neurofilament subunit.Neurology58, 1372-1381.
45.
BartosA, FialovaL, SoukupovaJ, KukalJ, MalbohanI, Pit’haJ (2007) Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.J Neurol254, 20-25.
46.
BartosA, FialovaL, SoukupovaJ, KukalJ, MalbohanI, PithaJ (2007) Antibodies against light neurofilaments in multiple sclerosispatients.Acta Neurol Scand116, 100-107.
47.
FialovaL, BartosA, SvarcovaJ, MalbohanI (2011) Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis.PLoS One6, e27476.
48.
HimmlerA, DrechselD, KirschnerMW, MartinDWJr (1989) Tauconsists of a set of proteins with repeated C-terminalmicrotubule-binding domains and variable N-terminal domains.Mol Cell Biol9, 1381-1388.
49.
vanZwam M, HuizingaR, MeliefMJ, Wierenga-WolfAF, vanMeurs M, VoermanJS, BiberKP, BoddekeHW, HopkenUE, MeiselC, MeiselA, BechmannI, HintzenRQ, tHart BA, AmorS, LamanJD, BovenLA (2009) Brain antigens in functionally distinct antigen-presenting cellpopulations in cervical lymph nodes in MS and EAE.J Mol Med(Berl)87, 273-286.
50.
MruthintiS, BuccafuscoJJ, HillWD, WallerJL, JacksonTW, ZamriniEY, SchadeRF (2004) Autoimmunity in Alzheimer’s disease: Increasedlevels of circulating IgGs binding Abeta and RAGE peptides.Neurobiol Aging25, 1023-1032.
51.
FialováL, BartosA, šSvarcováJ, MalbohanI (2012) Tauprotein and anti-tau antibodies in patients with multiple sclerosis.Cesk Slov Neurol N75/108, 310-313.
52.
PerryG, FriedmanR, KangDH, ManettoV, Autilio-GambettiL, GambettiP (1987) Antibodies to the neuronal cytoskeleton areelicited by Alzheimer paired helical filament fractions.BrainRes420, 233-242.
53.
MarcelloA, WirthsO, Schneider-AxmannT, Degerman-GunnarssonM, LannfeltL, BayerTA (2011) Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Abeta in plasma of patients with Alzheimer’s disease.Neurobiol Aging32, 1379-1387.
54.
JianpingL, ZhibingY, WeiQ, ZhikaiC, JieX, JinbiaoL (2006) Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease.Alzheimer Dis Assoc Disord20, 127-132.
55.
KronimusY, AlbusA, Balzer-GeldsetzerM, StraubS, SemlerE, OttoM, KlotscheJ, DodelR, ConsortiumL, MengelD (2016) Naturally occurring autoantibodies against tau protein are reduced in Parkinson’s disease dementia.PLoS One11, e0164953.
56.
HuizingaR, LiningtonC, AmorS (2008) Resistance is futile:Antineuronal autoimmunity in multiple sclerosis.Trends Immunol29, 54-60.
57.
GrudenMA, DavudovaTB, MalisauskasM, ZamotinVV, SewellRD, VoskresenskayaNI, KostanyanIA, SherstnevVV, Morozova-RocheLA (2004) Autoimmune responses to amyloid structures of Abeta(25-35)peptide and human lysozyme in the serum of patients with progressive Alzheimer’s disease.Dement Geriatr Cogn Disord18, 165-171.
58.
HuizingaR, HeijmansN, SchubertP, GschmeissnerS, tHart BA, HerrmannH, AmorS (2007) Immunization with neurofilament light xprotein induces spastic paresis and al degeneration in BiozziABH mice.J Neuropathol Exp Neurol66, 295-304axon.
59.
BartosA, StouracP, RusinaR, SejdovaM, VelenskaZ (2002) [Paraneoplastic cerebellar degeneration associated with ovariancancer: Anti-Yo immunoreactivity in autoptic cerebellum and ovariancarcinoma].Nervenarzt73, 995-998.
60.
GrausF, SaizA, DalmauJ (2010) Antibodies and neuronal auto immunedisorders of the CNS.J Neurol257, 509-517.
61.
FialovaL, BartosA, SvarcovaJ (2017) Neurofilaments and tauproteins in cerebrospinal fluid and serum in dementias andneuroinflammation.Biomed Pap Med Fac Univ Palacky OlomoucCzech Repub161, 286-295.
